The once-monthly RNA interference injection medication received FDA approval based on results from the phase II PHYOX2 clinical trial and phase III PHYOX3 extension study.
A recent phase 3 trial showed that for untreated patients with chronic lymphocytic leukemia, measurable residual disease-directed ibrutinib–venetoclax therapy had superior progression-free survival compared...
Researchers evaluated whether patients with atherosclerotic cardiovascular disease (ASCVD) are utilizing high-intensity statins in their routine care of the disease.
The FDA approved pirtobrutinib for adults with either chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.
A new set of guidelines detail recommendations for the best practice in managing acute dental pain in children after tooth extractions or during toothache.
Using data from the Centers for Medicare & Medicaid Services Chronic Conditions Warehouse database, researchers set out to estimate the risk of gout following recombinant zoster vaccination among adults...
Researchers conducted a retrospective analysis of 469 patients with HR+/HER2- metastatic breast cancer and cardiovascular diseases treated with palbociclib plus aromatase inhibitors or aromatase inhibitors...
This COVID-19 roundup includes coverage of the FDA’s guidance for the correct Moderna vaccine dosage for pediatric patients, COVID-19 outcomes for patients with hypertension and diabetes, and the risk of...